Restoration of Dopamine Transporter Density in the Striatum of Fetal Ventral Mesencephalon-Grafted, but not Sham-Grafted, Mptp-Treated Parkinsonian Monkeys

• Abstract — Transplantation of fetal dopamine neurons to the adult striatum potentially offers a means to reverse the striatal dopamine deficiency that characterizes Parkin­ son's disease. Many investigations in rodents have sup­ ported the hope that neural grafting may be a useful treat­ ment for parkinsonism. However, clinical studies have generally produced more modest improvements in motor abnormalities than observed in lower species. It is possible that the number of fetal dopamine neurons that survive transplantation is insufficient to restore dopaminergic in­ nervation of the large human striatum to a level where striking recovery is obtained. In fact, there has been no quantitative study of graft outgrowth to indicate what por­ tion of the dopamine-depleted striatum might be reinnervated with present techniques. Furthermore, it has been speculated that regeneration of the host dopamine system in response to the implantation surgery may play an impor­ tant role in the beneficial effects of neural grafting in pri­ mates. The present study used nine l-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys to investigate these issues. Sham implantation procedures produced no increase in either dopamine trans­ porter density (measured by quantitative autoradiography) or tissue dopamine concentration (measured by HPLC) in the striatum of MPTP-treated monkeys. In sham-grafted and nonimplanted MPTP-treated monkeys, the striatal do­ pamine concentration was reduced by 99%, based on analy­ sis of 16 sampled sites in the caudate nucleus and putamen of each monkey. No behavioral recovery was seen in the sham-grafted and nonimplanted MPTP-treated groups. In contrast, transplantation of fetal dopamine neurons to the caudate nucleus or putamen of MPTP-treated monkeys re­ sulted in a significant elevation of dopamine transporter density and dopamine levels in the grafted striatal nucleus. Each grafted MPTP-treated monkey received ventral mes­ encephalon dopamine neurons from one donor harvested during putative neurogenesis. Donor ventral mesencepha­ lon was divided equally and implanted into six sites either in the caudate nucleus or putamen. One graft site in each monkey was examined by dopamine transporter autoradi­ ography. In sections in which graft fibers were present, a mean of one-third of the volume of the grafted nucleus was occupied by an elevated density of dopamine transporters. This increase in dopamine transporter density was defined to be at least 5-10% of the control density. However, full behavioral recovery was not observed in the grafted MPTPtreated group. These data provide no support for the hy­ pothesis that regeneration of the host dopamine system oc­ curs in response to a sham implantation procedure in severely parkinsonian monkeys. The current study illus­ trates the power of the applied techniques for delineating the relationship between the level of host dopamine deple­ tion, the extent of graft-induced dopaminergic restoration, and behavioral recovery.

[1]  R. Roth,et al.  Early gestational mesencephalon grafts, but not later gestational mesencephalon, cerebellum or sham grafts, increase dopamine in caudate nucleus of MPTP-treated monkeys , 1996, Neuroscience.

[2]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[3]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[4]  R. Roth,et al.  Sham Surgery does not Ameliorate MPTP-Induced Behavioral Deficits in Monkeys , 1995 .

[5]  J. Naegele,et al.  Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase , 1994, Science.

[6]  T. Collier,et al.  Neural graft augmentation through co-grafting: Implantation of cells as sources of survival and growth factors , 1994, Progress in Neurobiology.

[7]  R. Roth,et al.  Can Graft-Derived Neurotrophic Activity Be Used to Direct Axonal Outgrowth of Grafted Dopamine Neurons for Circuit Reconstruction in Primates? , 1993, Experimental Neurology.

[8]  M. Sofroniew,et al.  Trophism, Transplantation, and Animal Models of Parkinson's Disease , 1993, Experimental Neurology.

[9]  Y. Agid,et al.  Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? , 1993, Neuroscience.

[10]  R. Roth,et al.  Fetal Dopamine Cell Survival after Transplantation Is Dramatically Improved at a Critical Donor Gestational Age in Nonhuman Primates , 1993, Experimental Neurology.

[11]  C D Marsden,et al.  Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study , 1993, Synapse.

[12]  A. Björklund Better cells for brain repair , 1993, Nature.

[13]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[14]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[15]  A. Björklund Dopaminergic transplants in experimental parkinsonism: Cellular mechanisms of graft induced functional recovery , 1992, Current Biology.

[16]  M. Kuhar,et al.  Isopropyl and phenyl esters of 3 beta-(4-substituted phenyl)tropan-2 beta-carboxylic acids. Potent and selective compounds for the dopamine transporter. , 1992, Journal of medicinal chemistry.

[17]  O. Lindvall Prospects of transplantation in human neurodegenerative diseases , 1991, Trends in Neurosciences.

[18]  A. Björklund Neural transplantation — an experimental tool with clinical possibilities , 1991, Trends in Neurosciences.

[19]  R. Artymyshyn,et al.  The use of 3H standards in 125I autoradiography , 1990, Journal of Neuroscience Methods.

[20]  R. Roth,et al.  MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.

[21]  D. Jacobowitz,et al.  The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. , 1990, Journal of neurosurgery.

[22]  R. Roth,et al.  Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.

[23]  J. Parisi,et al.  Effects of l‐Methyl‐4‐Phenyl‐l,2,3,6‐Tetrahydropyridine in the Dog: Effect of Pargyline Pretreatment , 1989, Journal of neurochemistry.

[24]  J. Kordower,et al.  Adrenal medullary autografts into the basal ganglia of Cebus monkeys: Injury-induced regeneration , 1988, Experimental Neurology.

[25]  R. Roth,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.

[26]  Richard F. Martin,et al.  Primate neostriatal neurons containing tyrosine hydroxylase: Immunohistochemical evidence , 1987, Neuroscience Letters.

[27]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[28]  W. Freed Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutic trials. , 1991, Restorative neurology and neuroscience.

[29]  D. Jacobowitz,et al.  Fetal nondopaminergic neural implants in parkinsonian primates. Histochemical and behavioral studies. , 1991, Journal of neurosurgery.

[30]  E. Oldfield,et al.  Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites. , 1990, Progress in brain research.

[31]  D. Jacobowitz,et al.  Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. , 1988, Progress in brain research.

[32]  A. Hendrickx,et al.  Prenatal growth in the cynomolgus and rhesus macaque (Macaca fascicularis and Macaca mulatta): A comparison by ultrasonography , 1988, American journal of primatology.

[33]  A. Björklund,et al.  Can human fetal dopamine neuron grafts provide a therapy for Parkinson's disease? , 1988, Progress in brain research.

[34]  R. Roth,et al.  Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. , 1988, Progress in brain research.

[35]  D. Jacobowitz,et al.  N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. , 1984, Psychopharmacology bulletin.